The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review
Our review of economic evaluations of genomic medicine in cancer control, led by our PhD Candidate Mackenzie Bourke and A/Prof Ilias Goranitis, was published in the Applied Health Economics and Health Policy journal. The development of the paper was supported from Cancer Australia and the World Health Organisation, and has been one of the top 5 most downloaded articles of the journal in 2025.
The article examines the current literature regarding the cost-effectiveness of genomic medicine across the cancer care continuum, from prevention and early detection to palliative and end-of-life care. The review found convergent evidence for the cost-effectiveness of genomic medicine in the management of several cancers, including prevention and detection of breast, ovarian, endometrial and colorectal cancers, and the treatment of breast and advanced lung cancer, among others.
The scale of the work demonstrates the most comprehensive review of economic evidence for genomic medicine and cancer to date. This synthesis provides important evidence to guide policy for the sustainable implementation of genomic medicine. The work formed the foundation of the health economics component of the evidence review that informed the development of Cancer Australia’s National Framework for Genomics in Cancer Control. The framework aims to support people affected by cancer to benefit from cancer genetic testing and genomics-informed treatments. The Framework will guide policy for equitable access to personalised cancer care for all Australians affected by cancer.
The full article can be found here: https://link.springer.com/article/10.1007/s40258-025-00949-w#Sec38